Cipla, Dr Reddy’s, Viatris And Teva Named In US Revlimid Antitrust Suit
ANDA Sponsors ‘Restrained Competition And Maintained Shared Monopoly’
Months after the first generic versions of Bristol-Myers Squibb’s multi-billion-dollar blockbuster Revlimid (lenalidomide) debuted in the US, indirect purchasers of the treatment for multiple myeloma have accused the originator and a raft of settling ANDA sponsors that their deals were anticompetitive.
